Urgent vs. Early Endoscopy in High Risk Patients With Upper Gastrointestinal Bleeding (UGIB)
Launched by CHINESE UNIVERSITY OF HONG KONG · Aug 28, 2012
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
The GBS, being a pre-endoscopy score with clinical parameters, is more suitable for patient triage leading to urgent endoscopy and a higher level of care. A GBS of 0 has been shown to identify patients with upper gastrointestinal bleeding who may be managed safely as outpatients. The proportion of patients requiring endoscopic therapy increases with a higher score. A cut-off score that identifies "high-risk" patients who may benefit from urgent intervention however has not been determined. Guidelines from Societies around the world recommend early endoscopy within 24 hours of presentation f...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Overt signs of upper gastrointestinal bleeding (i.e., melena or hematemesis with or without hypotension)
- • 2. GBS of ≥12
- • 3. In-patients admitted for reasons other than AUGIB who develop bleeding are also considered for trial enrollment.
- • 4. Patients in Hypotensive shock (SBP ≤90 mmHg or pulse ≥110 bpm) are initially resuscitated and then considered for trial entry if their condition can be stabilized.
- Exclusion Criteria:
- • 1. continued shock despite initial volume resuscitation (refractory shock) undergo urgent endoscopy
- • 2. \< 18 years of age
- • 3. Unable to provide written informed consent
- • 4. Pregnant or lactating women
- • 5. Moribund patients from terminal illnesses. (active treatment not considered)
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , China
Patients applied
Trial Officials
James Y LAU, MD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials